Narcolepsy Market Report 2026

The narcolepsy market size has grown rapidly in recent years. It will grow from $3.95 billion in 2025 to $4.38 billion in 2026 at a compound annual growth rate (CAGR) of 10.8%. The growth in the historic period can be attributed to limited awareness of narcolepsy, delayed diagnosis rates, reliance on stimulant medications, introduction of sodium oxybate, growth in sleep disorder research.

The narcolepsy market size is expected to see rapid growth in the next few years. It will grow to $6.62 billion in 2030 at a compound annual growth rate (CAGR) of 10.9%. The growth in the forecast period can be attributed to rising prevalence of sleep disorders, increasing r&d investment, expanding non-stimulant therapeutic pipeline, growing patient education initiatives, advancements in precision medicine approaches. Major trends in the forecast period include rising awareness and diagnosis of narcolepsy, increasing adoption of combination therapy, growing demand for long-acting therapeutics, expansion of non-stimulant treatment options, enhanced focus on cataplexy-specific therapeutics.

The rising prevalence of obesity is expected to drive the growth of the narcolepsy market going forward. Obesity is a medical condition marked by excessive body fat accumulation that increases health risks. Its prevalence is rising due to sedentary lifestyles, poor dietary habits, and environmental factors that promote high-calorie food consumption and reduce physical activity. Obesity may contribute to narcolepsy by disrupting metabolic and hormonal balances, affecting sleep regulation and wakefulness patterns. For instance, in May 2025, according to the Office for Health Improvement & Disparities, a UK-based government department, approximately 64.5% of adults aged 18 and over in England were overweight or living with obesity in 2023-2024, up from 64% in 2022-2023, indicating a continuing upward trend. Therefore, the growing prevalence of obesity is fueling the growth of the narcolepsy market.

Major companies in the narcolepsy market are focusing on the development of novel medications, such as extended-release sodium oxybate, to meet the demand for effective and convenient treatments. Extended-release sodium oxybate provides controlled medication release over an extended period, offering sustained symptom relief throughout the night and improving sleep quality for narcolepsy patients. For instance, in June 2023, Avadel Pharmaceuticals plc, an Ireland-based pharmaceutical company, launched LUMRYZ in the United States. LUMRYZ is an FDA-approved extended-release formulation of sodium oxybate for treating cataplexy or excessive daytime sleepiness in adults with narcolepsy. It is the first once-at-bedtime oxybate therapy, improving on twice-nightly formulations by eliminating the need for a second dose at night.

In December 2023, NLS Pharmaceutics AG, a Switzerland-based pharmaceutical company, acquired a dual orexin receptor agonist platform from Aexon Labs Inc. for an undisclosed amount. This acquisition provides NLS Pharmaceutics with the option to in-license all of Aexon Labs’ assets for narcolepsy and other neurodegenerative disorders, including global rights to multiple highly selective orexin-1/orexin-2 receptor agonists. Aexon Labs Inc. is a US-based company developing treatments for narcolepsy and neurodegenerative diseases.

Major companies operating in the narcolepsy market are Pfizer Inc., Merck & Co. Inc, Novartis AG, Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries, Otsuka Pharmaceutical, Sumitomo Pharma Company Limited, Jazz Pharmaceuticals, Alkermes, Harmony Biosciences, Cerevel Therapeutics, Axsome Therapeutics Inc., Avadel Pharmaceuticals, NLS Pharmaceutics AG, KemPharm, Bioprojet Pharma, Centessa Pharmaceuticals, Hikma Pharmaceuticals, Theranexus SA, Eisai Co Ltd, Ligand Pharmaceuticals, Graymark Healthcare Inc, H Lundbeck A/S.

North America was the largest region in the narcolepsy market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the narcolepsy market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the narcolepsy market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have influenced the narcolepsy market by increasing the cost of imported diagnostic devices, sleep study equipment, and pharmaceutical ingredients used in stimulant and sodium oxybate therapies. Hospitals and retail pharmacies in North America and Europe are the most affected due to reliance on international drug and equipment suppliers. These cost increases have slightly constrained treatment affordability. At the same time, tariffs are promoting domestic pharmaceutical production, improving long-term drug supply stability.

The narcolepsy market research report is one of a series of new reports that provides narcolepsy market statistics, including narcolepsy industry global market size, regional shares, competitors with a narcolepsy market share, detailed narcolepsy market segments, market trends and opportunities, and any further data you may need to thrive in the narcolepsy industry. This narcolepsy market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Narcolepsy is a chronic neurological disorder that disrupts the brain’s ability to regulate sleep-wake cycles. Individuals with narcolepsy often experience excessive daytime sleepiness and uncontrollable episodes of falling asleep, which can occur during any activity. The condition is frequently accompanied by cataplexy, a sudden loss of muscle tone triggered by strong emotions.

The main types of narcolepsy are type 1 and type 2. Type 1 narcolepsy (NT1) is characterized by excessive daytime sleepiness and cataplexy. Treatment options for narcolepsy include antidepressants, stimulants, sodium oxybate, and other therapies, while diagnosis typically involves a polysomnogram and multiple sleep latency tests. These treatments and diagnostic services are used by end users such as hospitals, retail pharmacies, and other healthcare providers.

The narcolepsy market consists of revenues earned by entities by providing services such as cognitive behavioral therapy, telemedicine consultations, lifestyle management programs, and patient education programs. The market value includes the value of related goods sold by the service provider or included within the service offering. The narcolepsy market also includes sales of dietary supplements, Pitolisant, Modafinil, and Armodafinil. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.